` NYKD (Nykode Therapeutics ASA) vs Oslo OBX Comparison - Alpha Spread

NYKD
vs
Oslo OBX

Over the past 12 months, NYKD has underperformed Oslo OBX, delivering a return of -85% compared to the Oslo OBX's 16% growth.

Stocks Performance
NYKD vs Oslo OBX

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
NYKD vs Oslo OBX

Loading
NYKD
Oslo OBX
Difference

Performance By Year
NYKD vs Oslo OBX

Loading
NYKD
Oslo OBX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Nykode Therapeutics ASA vs Peers

Oslo OBX
NYKD
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Nykode Therapeutics ASA
Glance View

Market Cap
954.8m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.18 NOK
Overvaluation 94%
Intrinsic Value
Price
N
Back to Top